CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL
NCT05659628
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
24
Enrollment
OTHER
Sponsor class
Conditions
Diffuse Large B-cell Lymphoma
Interventions
COMBINATION_PRODUCT:
CD19-7×19 CAR-T combined with Tislelizumab
Sponsor
Ningbo No. 1 Hospital
Collaborators
[object Object]